CEO says Pfizer not worried about expiring patents, generic competition

Pfizer rivals may be concerned about competition from generics, but the pharmaceutical firm is prepared to deal with the expiration of its patents on several major drugs over the next three years, CEO Henry McKinnell said. Other companies were hurt by expiring patents because they "failed to anticipate or lacked the means to respond," he said. McKinnell indicated Pfizer currently has as many as 20 drugs to submit for approval by the end of 2006.

View Full Article in:

Wall Street Journal (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Wayzata, MN
Meridian Health Plan
Detroit, MI